December 2022. Volume 18. Number 4

Enteral recombinant insulin could accelerate complete oral tolerance in preterm infants

 
 
 
 
 
 
 
 
 
 
Rating: 0 (0 Votes)
Newsletter Free Subscription
Regularly recieve most recent articles by e-mail
Subscribe
Print
Add to library
Discuss this article

AVC | Critically appraised articles

Mank E, Sáenz de Pipaón M, Lapillonne A, Carnielli VP, Senterre T, Shamir R, et al. Efficacy and safety of enteral recombinant human insulin in preterm infants: A randomized clinical trial. JAMA Pediatr. 2022;176:452-60.

Reviewers: Molina Arias M1, Aparicio Rodrigo M2.
1Servicio de Gastroenterología. Hospital Infantil Universitario La Paz. Madrid. España.
2Pediatra. CS Entrevías. Facultad de Medicina. Universidad Complutense de Madrid. Madrid. España.
Correspondence: Manuel Molina Arias. Email: mma1961@gmail.com
Reception date: 02/11/2022
Acceptance date: 14/11/2022
Publication date: 21/12/2022

Abstract

Authors´ conclusions: enteral administration of recombinant human insulin could favor the acquisition of full enteral feeding in preterm infants. Additional studies are necessary to determine the optimal dose and its efficacy in the most immature groups of neonates.

Reviewers´ commentary: enteral administration of 2 different recombinant human insulin dosages was safe and compared with placebo, significantly reduced time to full enteral feeding in preterm infants with a gestational age of 26 to 32 weeks.

How to cite this article

Molina Arias M, Aparicio Rodrigo M. La insulina recombinante enteral podría acelerar la tolerancia oral completa en niños prematuros. Evid Pediatr. 2022;18:39.

AVC | Critically appraised articles

Mank E, Sáenz de Pipaón M, Lapillonne A, Carnielli VP, Senterre T, Shamir R, et al. Efficacy and safety of enteral recombinant human insulin in preterm infants: A randomized clinical trial. JAMA Pediatr. 2022;176:452-60.

Reviewers: Molina Arias M1, Aparicio Rodrigo M2.
1Servicio de Gastroenterología. Hospital Infantil Universitario La Paz. Madrid. España.
2Pediatra. CS Entrevías. Facultad de Medicina. Universidad Complutense de Madrid. Madrid. España.
Correspondence: Manuel Molina Arias. Email: mma1961@gmail.com
Reception date: 02/11/2022
Acceptance date: 14/11/2022
Publication date: 21/12/2022

How to cite this article

Molina Arias M, Aparicio Rodrigo M. La insulina recombinante enteral podría acelerar la tolerancia oral completa en niños prematuros. Evid Pediatr. 2022;18:39.

21/12/2022

Linked Comment